HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective
Open Access
- 6 May 2015
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 13 (3) , 250-257
Abstract
The efficacy of combination therapy (antiretroviral therapy - ARV) is demonstrated by the high rates of viral suppression achieved in most treated HIV patients. Whereas contemporary treatments may continuously suppress HIV replication, they do not eliminate the latent reservoir, which can reactivate HIV infection if ARV is discontinued. The persistence of HIV proviral DNA and infectious viruses in CD4+ T cells and others cells has long been considered a major obstacle in eradicating the HIV virus in treated patients. Moreover, recent studies have demonstrated the persistence of HIV replication at low copies in most patients on suppressive ARV. The source of this ‘residual viraemia’ and whether it declines over years of therapy remain unknown. Similarly, little is known regarding the biological relationships between the HIV reservoir and viral replication at low copies. The question of whether this ‘residual viraemia’ represents active replication or the release of non-productive virus from the reservoir has not been adequately resolved. From a clinical perspective, both the quantification of the HIV reservoir and the detection of low levels of replication in full-responder patients on prolonged ARV may provide important information regarding the effectiveness of treatment and the eradication of HIV. To date, the monitoring of these two parameters has been conducted only for research purposes; the routine use of standardised tests procedure is lacking. This review aims to assess the current data regarding the correlation between HIV replication at low copies and the HIV reservoir and to provide useful information for clinicians.Keywords
This publication has 96 references indexed in Scilit:
- Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected PatientsAntimicrobial Agents and Chemotherapy, 2014
- The significance of low‐level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)HIV Medicine, 2014
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trialsAIDS, 2012
- SAMHD1 restricts HIV-1 infection in resting CD4+ T cellsNature Medicine, 2012
- Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week StudyAntiviral Therapy, 2011
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsNature Medicine, 2010
- HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral TherapyPLOS ONE, 2009
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failureProceedings of the National Academy of Sciences, 1997